Obinutuzumab (Genetical Recombination) for Intravenous Infusion 1000mg (Gazyva® / ガザイバ点滴静注1000mg)

JPY ¥550,600

Japanese antineoplastic humanized anti-CD20 monoclonal antibody (Obinutuzumab 1000mg/40mL). For intravenous infusion in CD20-positive follicular lymphoma and chronic lymphocytic leukemia. 40mL x 1 vial. Mfd. by Chugai Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥506,552
10 - 19 12% JPY ¥484,528
20 + 18% JPY ¥451,492
SKU: GAZ-1000-INJ Category:

Description

Product Overview / 商品概要

Gazyva for Intravenous Infusion 1000mg (ガザイバ点滴静注1000mg)
Generic: Obinutuzumab (Genetical Recombination) / オビヌツズマブ(遺伝子組換え)
Therapeutic Category: Antineoplastic Agent, Humanized Anti-CD20 Monoclonal Antibody / 抗悪性腫瘍剤 ヒト化抗CD20モノクローナル抗体
Manufactured by: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Obinutuzumab (Genetical Recombination) 1000mg per 1 vial (40.0mL) / 1バイアル(40.0mL)中 オビヌツズマブ(遺伝子組換え)1000mg
Additives: Per 1 vial (40.0mL): Trehalose hydrate 3632.0mg, L-Histidine 57.6mg, L-Histidine hydrochloride hydrate 89.6mg, Polyoxyethylene (160) polyoxypropylene (30) glycol 8.0mg (contains dibutylhydroxytoluene as antioxidant) / 1バイアル(40.0mL)中 トレハロース水和物 3632.0mg、L-ヒスチジン 57.6mg、L-ヒスチジン塩酸塩水和物 89.6mg、ポリオキシエチレン(160)ポリオキシプロピレン(30)グリコール 8.0mg(抗酸化剤としてジブチルヒドロキシトルエンを含む)
Appearance: Colorless to slightly brownish solution; pH 5.7–6.3; Osmolarity ratio 0.9–1.2 (relative to physiological saline)
外観: 無色~微褐色の液、pH 5.7~6.3、浸透圧比 0.9~1.2(生理食塩液に対する比)

Indications / 効能効果

EN: CD20-positive follicular lymphoma; CD20-positive chronic lymphocytic leukemia (including small lymphocytic lymphoma)
JA: CD20陽性の濾胞性リンパ腫、CD20陽性の慢性リンパ性白血病(小リンパ球性リンパ腫を含む)

Dosage and Administration / 用法用量

EN: Usually, in adults, 1000mg is administered once daily by intravenous infusion as obinutuzumab (genetical recombination). During induction therapy, administration is on Days 1, 8, and 15 of Cycle 1, and Day 1 of subsequent cycles. During maintenance therapy, 1000mg is administered as monotherapy once every 2 months for up to 2 years. In combination with cyclophosphamide hydrate, doxorubicin hydrochloride, vincristine sulfate, and prednisolone or methylprednisolone: 3-week cycle, 8 cycles. In combination with cyclophosphamide hydrate, vincristine sulfate, and prednisolone or methylprednisolone: 3-week cycle, 8 cycles. In combination with bendamustine hydrochloride: 4-week cycle, 6 cycles. In combination with acalabrutinib, usually in adults, 100mg on Day 1, 900mg on Day 2, and 1000mg on Days 8 and 15 of Cycle 1; 1000mg on Day 1 of Cycle 2 and beyond. 28-day cycle, up to 6 cycles.
JA: 〈CD20陽性の濾胞性リンパ腫〉通常、成人には、オビヌツズマブ(遺伝子組換え)として1日1回1000mgを点滴静注する。導入療法は、1サイクル目は1、8、15日目、2サイクル目以降は1日目に投与する。維持療法では、単独投与により2カ月に1回、最長2年間、投与を繰り返す。シクロホスファミド水和物、ドキソルビシン塩酸塩、ビンクリスチン硫酸塩及びプレドニゾロン又はメチルプレドニゾロン併用の場合:3週間を1サイクルとし、8サイクル。シクロホスファミド水和物、ビンクリスチン硫酸塩及びプレドニゾロン又はメチルプレドニゾロン併用の場合:3週間を1サイクルとし、8サイクル。ベンダムスチン塩酸塩併用の場合:4週間を1サイクルとし、6サイクル。〈CD20陽性の慢性リンパ性白血病(小リンパ球性リンパ腫を含む)〉アカラブルチニブとの併用において、通常、成人には、アカラブルチニブとの併用での1サイクル目の1日目に100mg、2日目に900mg、8日目及び15日目に1000mg、2サイクル目以降は1日目に1000mgを点滴静注する。28日間を1サイクルとし、最大で6サイクル投与を繰り返す。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 23000AMX00488
Sales Started: August 2018 / 2018年8月
Classification Code: 874291
Storage: Store at 2–8°C / 2~8℃保存
Shelf Life: 36 months / 36箇月

Packaging / 包装

Main Package (for sale): 40mL x 1 vial / 40mL×1バイアル
Other Available Packages (by special order): 40mL x 1 vial

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Obinutuzumab (Genetical Recombination) for Intravenous Infusion 1000mg (Gazyva® / ガザイバ点滴静注1000mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Obinutuzumab (Genetical Recombination) for Intravenous Infusion 1000mg (Gazyva®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.